Clonal evolution. Wheler was here too but she left before the photo. Proud of these mentees and wonderful opportunity to see them at TargetCancer Foundation meeting for rare cancers. 🧨🦄🦓🎯💡👏
🚨Which clinical specialties are shielded from AI, and which are exposed? New @NEJM_AI , the authors measure how much of each specialty's work requires in-person physical interaction and what that means for AI's reach into practice.
👉"Physical Limits to AI Substitution across Physician Specialties- Implications for the Physician Workforce" @NEJM@NEJM_AI@OncoAlertai.nejm.org/doi/full/10.1056…
🚨⭐️Your Outlook email may not be working & your flight may be delayed ✈️ so you might have a few minutes to read our Perspective, just published hot off the press @Nature@Nature_NPJ
👉Open access, free for all to read - at least @X & internet are working :) #precisionmedicine#AI
👉"AI-based prediction of actionable genomic alterations from H&E-stained slides" 🔬
👉Tissue exhaustion & slow turnaround still keep patients from the right targeted therapy. Deep learning models can now predict actionable genomic alterations directly from routine H&E, and the prospective EAGLE (EGFR, NSCLC) and ANNAR (FGFR, urothelial) studies show this holds across diverse global cohorts.
👉Near-instant, non-destructive results let us triage patients for molecular testing or clinical trials at the time of diagnosis. Every lab in the world makes an H&E slide, and this puts molecular information within reach of all of them @OncoAlert@oncodailynature.com/articles/s41698-0…
The TROP2/NMR/QCS/ paper is out @NatureMedicine 👉Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer
👉Scoring TROP2 IHC by eye doesn’t predict who benefits from TROP2 ADCs. Computational pathology does.
✅TROP2 QCS-NMR in TROPION-Lung01, NMR+ vs NMR–
👉Dato-DXd PFS 7.2 vs 4.0 mo (HR 0.40)
👉Docetaxel 4.1 vs 4.4 mo (HR 0.94)
👉An emerging predictive biomarker for Dato-DXd. #LCSM@OncoAlert@oncodailynature.com/articles/s41591-0…
Now this is a fantastic reason to return to X! Thank you, @Aiims1742, for the warm welcome. Thrilled to join @Perlmutter_CC, and grateful to you, @JohnPLeonardMD, and the superb PCC and #SuppOnc teams!
⭐️New city, new chapter, same mission 🗽
⭐️Thrilled to have joined @nyulangone@Perlmutter_CC to lead Early Phase Drug Development and the Rare Cancer Programs.
⭐️For patients with rare cancers, #PrecisionMedicine should open the door to treatment. Expanding access to early-phase trials is how we make that real.
⭐️My work has always been tumor-agnostic. That continues here, now geography agnostic & zip code agnostic too.
⭐️Such a delight to be in NY with family. Grateful to @Aiims1742, @JohnPLeonardMD & @nyuniversity@nyulangone visionary leadership for bringing me here!
⭐️Thank you to all my friends & colleagues for the wishes & the outpouring of support🙏
@OncoAlert@oncodaily@ASCO@ASCOPosttinyurl.com/238ks5m5
New online! An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval dlvr.it/TVv93k